Stereotaxis To Initiate First-In-Human Trial To Support CE Mark Application Of MAGiC Catheter
Portfolio Pulse from Benzinga Newsdesk
Stereotaxis (STXS) is set to initiate the first-in-human trial to support the CE Mark application of its MAGiC Catheter, a robotic magnetic navigation technology for cardiac procedures.
June 15, 2023 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stereotaxis is initiating a first-in-human trial for its MAGiC Catheter, which could lead to CE Mark approval and increased market potential.
The initiation of the first-in-human trial for Stereotaxis' MAGiC Catheter is a significant milestone for the company. If the trial is successful and the CE Mark is granted, it could lead to increased market potential for the product in Europe and other regions that recognize the CE Mark. This would likely have a positive impact on STXS stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100